Janssen reported a major milestone for teclistamab in refractory multiple myeloma through results from its MajesTEC-9 phase I/IIa trial. In a cohort of nearly 600 patients, teclistamab met its primary endpoint and showed improved progression-free and overall survival versus standard control therapies, with high complete response rates and substantial proportions reaching minimal residual disease (MRD) negativity. In pancreatic cancer, researchers highlighted a dual-action immunotherapy concept using CXCR2 antibodies to target both tumors and neutrophils, aiming to enhance responses to immunotherapy in ARID1A-deficient disease. The approach underscores a strategy of simultaneously modulating tumor microenvironment immunity and innate cell recruitment. Separately, work on cGAS–STING pathways continues to feed oncology combination thinking. A study identified USP30-AS1 micropeptide as a driver of tumor growth by suppressing macrophage cGAS–STING interferon signaling, adding to the growing map of how innate DNA sensing controls anti-tumor immunity.